Bristol-Myers Squibb UK has appointed Dr Véronique Walsh to the role of Business Unit Director, Neuroscience and Immunoscience.
She will lead the sales and marketing teams for the company’s neuroscience and immunoscience portfolio, including Orencia (abatacept), Abilify (aripiprazole) and Perfalgan (paracetamol IV), as well as other investigational products.
Dr Walsh joins from Sanofi Pasteur MSD UK where she served as Deputy Managing Director.
She will report to Vice President and General Manager of BMS UK, Amadou Diarra.
